 Dianna Quan
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polyneuropathies | 7 | 2022 | 50 | 1.890 |
Why?
| | Muscular Atrophy, Spinal | 2 | 2021 | 19 | 1.280 |
Why?
| | Amyloid Neuropathies, Familial | 3 | 2022 | 8 | 1.200 |
Why?
| | Motor Neuron Disease | 2 | 2021 | 16 | 0.830 |
Why?
| | Amyotrophic Lateral Sclerosis | 2 | 2021 | 60 | 0.800 |
Why?
| | Neural Conduction | 4 | 2018 | 78 | 0.780 |
Why?
| | Muscle, Skeletal | 3 | 2019 | 1468 | 0.700 |
Why?
| | Point Mutation | 2 | 2016 | 216 | 0.690 |
Why?
| | Muscle Weakness | 4 | 2018 | 81 | 0.640 |
Why?
| | Myositis | 1 | 2019 | 44 | 0.620 |
Why?
| | Prealbumin | 3 | 2022 | 22 | 0.590 |
Why?
| | Neuromuscular Diseases | 2 | 2008 | 89 | 0.560 |
Why?
| | Electromyography | 5 | 2021 | 326 | 0.560 |
Why?
| | TRPV Cation Channels | 1 | 2016 | 30 | 0.530 |
Why?
| | Critical Illness | 3 | 2018 | 643 | 0.510 |
Why?
| | Biopsy | 1 | 2019 | 1024 | 0.500 |
Why?
| | Polymyositis | 1 | 2011 | 15 | 0.370 |
Why?
| | Muscular Dystrophies | 1 | 2011 | 36 | 0.360 |
Why?
| | Pain | 1 | 2016 | 701 | 0.360 |
Why?
| | Multiple Sclerosis | 2 | 2005 | 372 | 0.350 |
Why?
| | Intensive Care Units | 6 | 2018 | 614 | 0.340 |
Why?
| | Electrodiagnosis | 2 | 2012 | 15 | 0.340 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 41 | 0.310 |
Why?
| | Nervous System Diseases | 1 | 2011 | 255 | 0.300 |
Why?
| | Diagnostic Errors | 1 | 2008 | 150 | 0.290 |
Why?
| | Patient Discharge | 3 | 2018 | 770 | 0.280 |
Why?
| | Diagnosis, Differential | 4 | 2016 | 1331 | 0.270 |
Why?
| | Antibodies | 1 | 2008 | 365 | 0.270 |
Why?
| | Neuralgia, Postherpetic | 1 | 2006 | 44 | 0.260 |
Why?
| | Valine | 1 | 2006 | 72 | 0.260 |
Why?
| | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2005 | 4 | 0.250 |
Why?
| | Acyclovir | 1 | 2006 | 100 | 0.250 |
Why?
| | Spinal Nerve Roots | 1 | 2005 | 27 | 0.250 |
Why?
| | Cranial Nerve Diseases | 1 | 2005 | 42 | 0.240 |
Why?
| | Neuralgia | 2 | 2021 | 122 | 0.230 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2005 | 120 | 0.230 |
Why?
| | Myasthenia Gravis | 1 | 2023 | 18 | 0.220 |
Why?
| | Activities of Daily Living | 2 | 2023 | 349 | 0.210 |
Why?
| | Humans | 25 | 2023 | 114080 | 0.200 |
Why?
| | Ketamine | 1 | 2003 | 92 | 0.190 |
Why?
| | Nortriptyline | 1 | 2021 | 5 | 0.180 |
Why?
| | Duloxetine Hydrochloride | 1 | 2021 | 8 | 0.180 |
Why?
| | Aged | 10 | 2021 | 18973 | 0.180 |
Why?
| | Antiviral Agents | 1 | 2006 | 642 | 0.180 |
Why?
| | Sural Nerve | 2 | 2014 | 19 | 0.180 |
Why?
| | Analgesics | 1 | 2021 | 156 | 0.160 |
Why?
| | Motor Neurons | 1 | 2021 | 213 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2003 | 330 | 0.160 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 534 | 0.150 |
Why?
| | Adult | 10 | 2021 | 30395 | 0.150 |
Why?
| | Female | 16 | 2021 | 59349 | 0.150 |
Why?
| | Middle Aged | 11 | 2021 | 26621 | 0.150 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 239 | 0.150 |
Why?
| | Male | 15 | 2021 | 55420 | 0.150 |
Why?
| | Pain Management | 1 | 2021 | 285 | 0.150 |
Why?
| | Rhabdomyolysis | 1 | 2015 | 16 | 0.130 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6307 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2022 | 9051 | 0.120 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 122 | 0.120 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1690 | 0.120 |
Why?
| | Prospective Studies | 4 | 2018 | 6198 | 0.110 |
Why?
| | Physical Exertion | 1 | 2015 | 209 | 0.110 |
Why?
| | Peroneal Nerve | 1 | 2014 | 19 | 0.110 |
Why?
| | Neurologic Examination | 1 | 2014 | 113 | 0.110 |
Why?
| | Electrophysiology | 1 | 2014 | 201 | 0.110 |
Why?
| | Muscle Strength | 1 | 2016 | 271 | 0.110 |
Why?
| | Muscular Diseases | 2 | 2017 | 104 | 0.110 |
Why?
| | Quality of Life | 2 | 2022 | 2346 | 0.110 |
Why?
| | Biomarkers | 1 | 2022 | 3397 | 0.100 |
Why?
| | Bed Rest | 1 | 2012 | 15 | 0.100 |
Why?
| | Immunoglobulins | 2 | 2009 | 143 | 0.090 |
Why?
| | Phenotype | 2 | 2016 | 2784 | 0.090 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1257 | 0.090 |
Why?
| | Physical Examination | 1 | 2011 | 221 | 0.080 |
Why?
| | Meningoencephalitis | 1 | 2009 | 24 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2019 | 12521 | 0.080 |
Why?
| | Physical Therapy Modalities | 1 | 2012 | 265 | 0.080 |
Why?
| | West Nile Fever | 1 | 2009 | 48 | 0.080 |
Why?
| | Frontal Lobe | 1 | 2010 | 141 | 0.080 |
Why?
| | Respiration, Artificial | 3 | 2018 | 528 | 0.080 |
Why?
| | Electrodes | 1 | 2008 | 99 | 0.080 |
Why?
| | Sepsis | 1 | 2014 | 507 | 0.080 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2010 | 481 | 0.070 |
Why?
| | Immunocompromised Host | 1 | 2009 | 192 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2009 | 217 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2009 | 244 | 0.070 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2007 | 22 | 0.070 |
Why?
| | Young Adult | 2 | 2019 | 10459 | 0.070 |
Why?
| | Injections, Intravenous | 1 | 2006 | 198 | 0.060 |
Why?
| | Peripheral Nervous System | 1 | 2005 | 17 | 0.060 |
Why?
| | Action Potentials | 1 | 2008 | 406 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 476 | 0.060 |
Why?
| | Guillain-Barre Syndrome | 1 | 2005 | 21 | 0.060 |
Why?
| | Neuropsychological Tests | 1 | 2010 | 926 | 0.060 |
Why?
| | Cranial Nerves | 1 | 2005 | 11 | 0.060 |
Why?
| | Executive Function | 1 | 2010 | 381 | 0.060 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2005 | 41 | 0.060 |
Why?
| | Adolescent | 3 | 2019 | 17811 | 0.060 |
Why?
| | Exercise | 1 | 2015 | 1641 | 0.060 |
Why?
| | Graves Disease | 1 | 2005 | 34 | 0.060 |
Why?
| | Hypertrophy | 1 | 2005 | 110 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2008 | 527 | 0.060 |
Why?
| | Friedreich Ataxia | 1 | 2005 | 64 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 662 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 330 | 0.060 |
Why?
| | Administration, Oral | 1 | 2006 | 725 | 0.060 |
Why?
| | Myelin Sheath | 1 | 2005 | 138 | 0.060 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2007 | 350 | 0.050 |
Why?
| | Central Nervous System | 1 | 2005 | 230 | 0.050 |
Why?
| | Axons | 1 | 2005 | 173 | 0.050 |
Why?
| | Drug Evaluation | 1 | 2003 | 77 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 949 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2003 | 117 | 0.050 |
Why?
| | Gels | 1 | 2003 | 72 | 0.050 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2002 | 27 | 0.050 |
Why?
| | Patients | 1 | 2023 | 163 | 0.050 |
Why?
| | North America | 1 | 2002 | 255 | 0.050 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2003 | 117 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 641 | 0.050 |
Why?
| | Pregabalin | 1 | 2021 | 9 | 0.050 |
Why?
| | Mexiletine | 1 | 2021 | 7 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2021 | 131 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 370 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 327 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2540 | 0.040 |
Why?
| | Hospital Charges | 1 | 2017 | 39 | 0.040 |
Why?
| | Propensity Score | 1 | 2017 | 225 | 0.030 |
Why?
| | APACHE | 1 | 2016 | 58 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1350 | 0.030 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 48 | 0.030 |
Why?
| | Creatine Kinase | 1 | 2015 | 75 | 0.030 |
Why?
| | Ultrasonography | 1 | 2018 | 635 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2005 | 3039 | 0.030 |
Why?
| | Brain | 1 | 2005 | 2355 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2017 | 773 | 0.030 |
Why?
| | Length of Stay | 1 | 2017 | 957 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1830 | 0.030 |
Why?
| | Patient Readmission | 1 | 2017 | 607 | 0.030 |
Why?
| | Respiratory Muscles | 1 | 2012 | 28 | 0.020 |
Why?
| | Mobility Limitation | 1 | 2012 | 60 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1791 | 0.020 |
Why?
| | Muscular Atrophy | 1 | 2012 | 78 | 0.020 |
Why?
| | Muscle Fatigue | 1 | 2012 | 94 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2012 | 271 | 0.020 |
Why?
| | Child | 1 | 2008 | 18408 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4092 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 82 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 4885 | 0.020 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2009 | 70 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2009 | 281 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 148 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6077 | 0.020 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2007 | 26 | 0.020 |
Why?
| | Graft Rejection | 1 | 2009 | 511 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 460 | 0.020 |
Why?
| | Pilot Projects | 1 | 2010 | 1361 | 0.020 |
Why?
| | Algorithms | 1 | 2012 | 1469 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2009 | 763 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 3315 | 0.010 |
Why?
| | Disease Progression | 1 | 2009 | 2371 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 3338 | 0.010 |
Why?
| | Infant | 1 | 2007 | 7946 | 0.010 |
Why?
|
|
Quan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|